EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data

Jiaqi Chen, Huirui Han, Lingxu Li, Zhengxin Chen, Xinying Liu, Tianyi Li, Xuefeng Wang, Qibin Wang, Ruijie Zhang, Dehua Feng, Lei Yu, Xia Li und 3 weitere

PeerJ · 2025

DOI: 10.7717/peerj.19078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Jiaqi Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedical Information and Engineering, Kidney Disease Research Institute at the Second Affiliated Hospital, Hainan Engineering Research C…. Hauptthemen laut MEDLINE: Drug Synergism, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hainan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Compared to single-drug therapy, combination therapy involves the use of two or more drugs to reduce drug dosage, decrease drug toxicity, and improve treatment efficacy. We developed an extreme gradient boosting (XGBoost)-based drug-drug cell line prediction model (XDDC) to predict synergistic drug combinations. XDDC was based on XGBoost and used one of the largest drug combination datasets, NCI-ALMANAC. In XDDC, drug chemical structures, adverse drug reactions, and target information were selected as drug features; gene expression, methylation, mutations, copy number variations, and RNA interference data were used as cell line features; and pathway information was incorporated to link drug features and cell line features. XDDC improved the interpretability of drug combination features and outperformed other machine learning methods. It achieved an area under the curve (AUC) of 0.966 ± 0.002 and an AUPR of 0.957 ± 0.002 when cross-validated on NCI-ALMANAC data. Different types of omics data were evaluated and compared in the model. Literature and experimental verification confirmed some of our predictions. XDDC could help medical professionals to rapidly screen synergistic drug combinations against specific cancer cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug SynergismNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansCell Line, TumorMachine LearningDrug CombinationsMultiomics

Stichwörter der Autor:innen

CancerDrug combinationDrug synergy predictionMachine learningMulti-omics

Substanzen

Drug CombinationsAntineoplastic Agents

Autor:innen und Institutionen

  • College of Biomedical Information and Engineering, Kidney Disease Research Institute at the Second Affiliated Hospital, Hainan Engineering Research Center for Health Big Data, Hainan Medical University, Haikou, Hainan,…

Förderung

  • Natural Science Foundation of Hainan Province
  • National Natural Science Foundation of China

Zitieren

APA

Chen, J., Han, H., Li, L., Chen, Z., Liu, X., Li, T., Wang, X., Wang, Q., Zhang, R., Feng, D., Yu, L., Li, X., Wang, L., Li, B., & Li, J. (2025). Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data. PeerJ. https://doi.org/10.7717/peerj.19078

Vancouver

Chen J, Han H, Li L, Chen Z, Liu X, Li T, et al. Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data. PeerJ. 2025. doi:10.7717/peerj.19078

BibTeX
@article{Chen2025,
  author = {Chen, Jiaqi and Han, Huirui and Li, Lingxu and Chen, Zhengxin and Liu, Xinying and Li, Tianyi and Wang, Xuefeng and Wang, Qibin and Zhang, Ruijie and Feng, Dehua and Yu, Lei and Li, Xia and Wang, Limei and Li, Bing and Li, Jin},
  title = {Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.19078}
}
Kostenlos starten →